title: The therapeutic potential of royal jelly in benign prostatic hyperplasia. Comparison with contemporary literature.
abstract: The aim of this study is to establish the scientific benefit of royal jelly (RJ) on prostatic-specific antigen (PSA), post-void residual (PVR) volume and International Prostate Symptom Score (IPSS) in benign prostatic hyperplasia. For the study, a group of 40 men were administered 38 mg of RJ over a period of three months, their PSA values, prostate volumes and the volumes of their transitory prostate zones, PVR and IPPS values were measured at the end of the first month, and at the end of the third month. The results of this study confirm the potential of RJ in reducing PSA scores and improving IPSS values. Since the use of RJ did not lead to any significant reduction in PVR, prostate volume, or to any involution of the transitory zone, it appears that it may only affect the blood marker of prostatic hyperplasia and to improve quality-of-life (QoL) in those patients. Overall, in comparison to phytotherapy and conventional therapy, RJ had similar positive effects on QoL in patients with BPH, however it exhibited markedly better effects on reducing PSA levels in blood. The therapeutical use of RJ exhibited no side effects.
authors.affiliation: a Urology and Nephrology Clinic and.
authors.forename: Bogdan
authors.initials: B
authors.lastname: Pajovic
authors.affiliation: b Department of Forensic Medicine , Clinical Centre of Montenegro, Faculty of Medicine, University of Montenegro , Podgorica , Montenegro.
authors.forename: Nemanja
authors.initials: N
authors.lastname: Radojevic
authors.affiliation: c Urology Clinic, Clinical Centre of Kragujevac , Kragujevac , Serbia , and.
authors.forename: Antonio
authors.initials: A
authors.lastname: Dimitrovski
authors.affiliation: d Faculty of Mathematics and Natural Sciences , University of Montenegro , Podgorica , Montenegro.
authors.forename: Savo
authors.initials: S
authors.lastname: Tomovic
authors.affiliation: a Urology and Nephrology Clinic and.
authors.forename: Marko
authors.initials: M
authors.lastname: Vukovic
mesh_terms: D000368:Aged; D005227:Fatty Acids / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009929:Organ Size / Q000187:drug effects; D011467:Prostate / Q000187:drug effects / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D014563:Urodynamics / Q000187:drug effects; D000099219:Royal Jelly
chemical_list: D005227:Fatty Acids; D017430:Prostate-Specific Antigen; D000099219:Royal Jelly
keywords: Benign prostatic hyperplasia; LUTS; PSA; post-void residual volume; royal jelly